News | June 17, 2008

Bracco Breaks the Mold with Cardiac PET Perfusion Imaging

June 18, 2008 – Bracco Diagnostics showcased its Cardiac PET Perfusion Imaging with CardioGen-82, a Rubidium Rb 82 generator and emphasized the advantages of cardiac PET Perfusion Imaging over the current SPECT, at the Society of Nuclear Medicine's 55th Annual Meeting.

The Rb-82/Sr-82 generator, which is FDA cleared, has Sr-82 on the column. When Sr-82 decays, it decays to a new daughter product called Rb-82. The physical half-life for Rb-82 is 75 seconds, which allows for an efficient protocol. By the time the imaging is completed for the rest portion (approximately 6 minutes), stress can follow immediately and then the stress images can be acquired (approximately 6 minutes). The study can be completed in approximately 40-45 minutes.

Key features of Rb-82 are that it has properties similar to Thallium-201 (Tl-201). Rb-82 acts as a potassium analog, allowing for a high extraction fraction at high flow rates. Defects are visualized within 2 – 7 minutes after injection. Due to the short T_ (75 seconds), both sets of images can be acquired using the same sized dose. A new 100 mCi generator arrives every 28 days. Fixed pricing allows many patients to be performed in a day without the hassle of ordering unit doses. All studies are performed under pharmacologic stress (e.g., adenosine, dipyridamole, or dobutamine)

Some of the advantages of cardiac PET Perfusion Imaging over the current SPECT, according to the company are: improved efficiency; lower radiation; exposure; less attenuation artifacts; and improved resolution.

For more information: www.bracco.com


Related Content

News | Contrast Media

August 17, 2023 β€” University of Missouri School of Medicine neurologist Adnan Qureshi, MD recently led a study that ...

Home August 17, 2023
Home
News | Contrast Media

July 3, 2023 β€” According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR) ...

Home July 03, 2023
Home
News | Contrast Media

May 11, 2021 β€” The American Institute of Ultrasound in Medicine (AIUM) and the American Society of Echocardiography (ASE ...

Home May 11, 2021
Home
Technology | Contrast Media

July 15, 2019 β€” The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic ...

Home July 15, 2019
Home
Videos | Contrast Media

Sharon Mulvagh, M.D., FASE, FACC, FRCPC, professor of medicine, division of cardiology, Dalhousie University, Halifax ...

Home June 28, 2019
Home
Feature | Contrast Media | Dave Fornell, Editor

Iodine-based contrast agents used in computed tomography (CT) and catheter-based angiography have been implicated as a ...

Home May 31, 2019
Home
News | Contrast Media

May 9, 2019 β€” Osprey Medical announced the launch of DyeMINISH, a global patient registry to evaluate the ongoing safety ...

Home May 09, 2019
Home
News | Contrast Media

November 30, 2018 β€” VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that ...

Home November 30, 2018
Home
News | Contrast Media

In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore ...

Home September 12, 2018
Home
News | Contrast Media

January 19, 2018 β€” Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced ...

Home January 19, 2018
Home
Subscribe Now